Trial Profile
The Randomized Controlled Trial for Evaluating the Efficacies of Tolvaptan in Patients with Chronic Kidney Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Furosemide
- Indications Renal failure
- Focus Therapeutic Use
- 11 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2020 Planned End Date changed from 31 Aug 2020 to 31 Mar 2021.
- 11 Dec 2019 Planned End Date changed from 30 Jul 2019 to 31 Aug 2020.